Does volumetric absorptive microsampling eliminate the hematocrit bias for caffeine and paraxanthine in dried blood samples? A comparative study
De Kesel, Lambert & Stove
The finding, in our words
VAMS eliminated the variable haematocrit bias seen with DBS, but a residual haematocrit-dependent recovery effect persisted at high haematocrit: the nuance that assays still need per-analyte validation.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
This study compared four dried blood spot devices for glucocorticoid detection, finding that the Mitra VAMS device offered the best combination of analytical recovery and user usability, whilst the HemaXis DB10 showed the least bias compared to whole blood.
The study developed and validated an LC-MS/MS method for THC, its metabolites and synthetic cannabinoids in both dried blood spots and VAMS, showing that VAMS eliminates the haematocrit effect that limits DBS accuracy, thereby providing a reliable tool for toxicological and anti-doping analysis in decentralised settings.
In AML and CLL, 91% of VAMS venetoclax results fell within 20% of plasma after individualised haematocrit correction; in home sampling, 18 of 21 patients self-sampled independently and 76% of returned samples were analysable, which shows home microsampling is workable, though the authors ask for multicentre validation.
The analysis indicates that dried blood spots and volumetric absorptive microsampling enable minimally invasive monitoring of prohibited substances, with volumetric absorptive microsampling offering improved quantitative reliability over traditional dried spots.
This review found that volumetric microsampling devices, such as Mitra, HemaPEN, HemaXis DB10, and Tasso-M20, overcome haematocrit bias, whilst Telimmune plasma separation cards enable direct plasma collection without centrifugation. These technologies support patient-centric, decentralised sampling, though the authors note that clinical validation remains limited across different drugs and patient populations.